1. (Original) An extended-release metformin tablet, comprising:

   a. from about 500 mg to about 1000 mg metformin,

   b. 5-25% w/w rate-controlling polymer(s), and

   c. other pharmaceutically acceptable excipients.

2. (Original) The extended-release tablet according to claim 1 comprising 850 mg metformin.

3. (Original) The extended-release tablet according to claim 1 comprising 1000 mg metformin.

4. (Original) The extended-release tablet according to claim 1 wherein metformin may be in the base form, or in the form of a pharmaceutically acceptable salt.

5. (Original) The extended-release tablet according to claim 4 wherein the pharmaceutically acceptable salt is hydrochloride, fumarate, hydrobromide, succinate or embonate.

6. (Original) The extended-release tablet according to claim 5 wherein the pharmaceutically acceptable salt is hydrochloride.

7. Cancelled.

8. Cancelled.

9. Cancelled.

10. Cancelled.

11. Cancelled.

12. Cancelled.

13. Cancelled.

14. Cancelled.

15. Cancelled.

16. (Original) The extended-release tablets according to claim 1 wherein the total tablet weight is not more than 1500 mg.

17. (Original) The extended-release tablets according to claim 1 wherein the tablets release metformin in a controlled manner over 12 hours.

18. (Original) The extended-release tablets according to claim 1 wherein the tablets release metformin over 24 hours.

19. (Original) The extended-release tablets of claim 1 further comprising one or more of sulfonylureas, insulin, glitazones, alpha-glucosidase inhibitors, meglitinides, fibrates, statins, squalene synthesis inhibitors and angiotensin-converting enzyme inhibitors.

20. (Original) A process for preparing extended-release metformin tablets, comprising:

a. blending metformin, 5-25% w/w rate-controlling polymers and other pharmaceutically acceptable excipients,

b. compacting / slugging,

c. milling or crushing the compacted / slugged material of step (b) into granules, and

d. lubricating and compressing the granules to form tablets.

21. Cancelled.

22. Cancelled.

23. Cancelled.

24. Cancelled.

25. Cancelled.

26. Cancelled.

27. Cancelled.

28. Cancelled.

29. Cancelled.

30. Cancelled.

31. Cancelled.

32. Cancelled.

33. Cancelled.

34. Cancelled.

35. Cancelled.

36. Cancelled.

37. Cancellled.

38. Cancelled.

39. Cancelled.

40. Cancelled.

41. (Original) A monolithic extended-release metformin tablet, comprising:

a. from about 500 mg to about 1000 mg metformin,

b. 5-25% w/w rate controlling polymer(s), and

c. other pharmaceutically acceptable excipients.

42. (Original) The extended-release tablet according to claim 41 comprising 850 mg metformin.

43. (Original) The extended-release tablet according to claim 41 comprising 1000 mg metformin.

44. (Original) The extended-release tablet according to claim 41 wherein metformin may be in its base form, or in the form of a pharmaceutically acceptable salt.

45. (Original) The extended-release tablet according to claim 44 wherein the pharmaceutically acceptable salt is hydrochloride, fumarate, hydrobromide, succinate or embonate.

46. (Original) The extended-release tablet according to claim 45 wherein the pharmaceutically acceptable salt is hydrochloride.

47. Cancelled.

48. Cancelled.

49. Cancelled.

50. Cancelled.

51. Cancelled.

52. Cancelled.

53. Cancelled.

54. Cancelled.

55. Cancelled.

56. (Original) The extended-release tablets according to claim 41 wherein the total tablet weight is not more than 1500 mg.

57. (Original) The extended-release tablets according to claim 41 wherein the tablets release metformin in a controlled manner over 12 hours.

58. (Original) The extended-release tablets according to claim 41 wherein the tablets release metformin over 24 hours.

59. (Original) The extended-release tablets of claim 41 further comprising one or more of sulfonylureas, insulin, glitazones, alpha-glucosidase inhibitors, meglitinides, fibrates, statins, squalene synthesis inhibitors and angiotensin-converting enzyme inhibitors.

60. (Original) A method for the treatment of non-insulin dependent diabetes mellitus in a patient in need thereof, comprising administering extended-release metformin tablets, comprising:

a. more than 500 mg metformin,

b. 5-25% w/w rate-controlling polymer(s), and

c. other pharmaceutically acceptable excipients.

61. (Original) The method according to claim 60 wherein the tablets may further include one or more of sulfonylureas, insulin, glitazones, alpha-glucosidase inhibitors, meglitinides, fibrates, statins, squalene synthesis inhibitors and angiotensin-converting enzyme inhibitors.